These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 10199749)

  • 1. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study.
    Ranke MB; Lindberg A; Chatelain P; Wilton P; Cutfield W; Albertsson-Wikland K; Price DA
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1174-83. PubMed ID: 10199749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS.
    Ranke MB; Lindberg A; Albertsson-Wikland K; Wilton P; Price DA; Reiter EO
    J Clin Endocrinol Metab; 2005 Apr; 90(4):1966-71. PubMed ID: 15634724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study.
    Ranke MB; Lindberg A; Chatelain P; Wilton P; Cutfield W; Albertsson-Wikland K; Price DA;
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4212-8. PubMed ID: 11095456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and calibration of the Kabi Pharmacia International Growth Study prediction model for children with idiopathic growth hormone deficiency.
    de Ridder MA; Stijnen T; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1223-7. PubMed ID: 12629110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth response in prepubertal children with idiopathic growth hormone deficiency during the first two years of treatment with human growth hormone. Analysis of the Kabi Pharmacia International Growth Study.
    Ranke MB; Guilbaud O
    Acta Paediatr Scand Suppl; 1991; 379():109-15; discussion 116. PubMed ID: 1815451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database).
    Ranke MB; Lindberg A; Cowell CT; Wikland KA; Reiter EO; Wilton P; Price DA;
    J Clin Endocrinol Metab; 2003 Jan; 88(1):125-31. PubMed ID: 12519840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of overweight on effectiveness of treatment with human growth hormone in growth hormone deficient children: analysis of German KIGS data.
    Reinehr T; Bechtold-Dalla Pozza S; Bettendorf M; Doerr HG; Gohlke B; Hauffa BP; Kaspers S; Land C; Mehls O; Schwab KO; Stahnke N; Ranke MB;
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):544-8. PubMed ID: 22006181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
    Ranke MB; Lindberg A; Price DA; Darendeliler F; Albertsson-Wikland K; Wilton P; Reiter EO;
    Horm Res; 2007; 68(2):53-62. PubMed ID: 17228181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment and validation of predictive model of short term responses to recombinant human growth hormone treatment in prepubertal short stature children with various growth hormone secretary statuses].
    Su Z; Li YH; Ma HM; Chen HS; DU ML; Gu YF
    Zhonghua Er Ke Za Zhi; 2008 Oct; 46(10):757-62. PubMed ID: 19099881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables.
    Ranke MB; Lindberg A;
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1229-37. PubMed ID: 20097713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. KIGS International Board. Kabi International Growth Study.
    Ranke MB; Lindberg A; Chatelain P; Wilton P; Cutfield W; Albertsson-Wikland K; Price DA
    Acta Paediatr Suppl; 1999 Dec; 88(433):122-5. PubMed ID: 10626562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
    Darendeliler F; Ranke MB; Bakker B; Lindberg A; Cowell CT; Albertsson-Wikland K; Reiter EO; Price DA
    Horm Res; 2005; 63(1):40-7. PubMed ID: 15627781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database).
    Geffner M; Lundberg M; Koltowska-Häggström M; Abs R; Verhelst J; Erfurth EM; Kendall-Taylor P; Price DA; Jonsson P; Bakker B
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5435-40. PubMed ID: 15531494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database.
    Reiter EO; Price DA; Wilton P; Albertsson-Wikland K; Ranke MB
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2047-54. PubMed ID: 16537676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone treatment of idiopathic short stature: analysis of the database from KIGS, the Kabi Pharmacia International Growth Study.
    Ranke MB; Lindberg A
    Acta Paediatr Suppl; 1994 Dec; 406():18-23; discussion 24. PubMed ID: 7734807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a mathematical model predicting the response to growth hormone treatment in prepubertal children with idiopathic growth hormone deficiency.
    Vosahlo J; Zidek T; Lebl J; Riedl S; Frisch H
    Horm Res; 2004; 61(3):143-7. PubMed ID: 14676463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the response to growth hormone treatment in short children with chronic kidney disease.
    Mehls O; Lindberg A; Nissel R; Haffner D; Hokken-Koelega A; Ranke MB
    J Clin Endocrinol Metab; 2010 Feb; 95(2):686-92. PubMed ID: 20008024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
    Zenaty D; Garel C; Limoni C; Czernichow P; Léger J
    Clin Endocrinol (Oxf); 2003 May; 58(5):647-52. PubMed ID: 12699449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.